Adagio Medical shares surge 20.75% premarket after publishing U.S. Early Feasibility Study results and highlighting $5.8B VT ablation market potential.

Adagio Medical Holdings, Inc. surged 20.75% in premarket trading following the release of a presentation detailing its U.S. Early Feasibility Study results for Ultra Low Temperature Cardiac Ablation (ULTC) technology. The presentation highlighted FDA approval expectations by late 2026, a $5.8 billion global market opportunity for ventricular tachycardia (VT) ablation, and the company’s competitive advantages, including proprietary technology and completed pivotal IDE enrollment. The news underscored Adagio’s positioning as a first-mover in an underserved market with high growth potential, driven by unmet clinical needs and a strong intellectual property position. These developments likely spurred investor optimism about the company’s long-term prospects and regulatory milestones.